”(P3) Rather, PCPs were more comfortable prescribing glucagon-like peptide receptor 1 agonists [GLP1-RAs], which are commonly used to treat patients with type 2 diabetes and increasingly used to treatment patients with obesity. Here, GLP1R is linked to obesity disorder.